行情

GALT

GALT

Galectin Thera
NASDAQ

实时行情|Nasdaq Last Sale

3.000
+0.050
+1.69%
休市 16:00 01/17 EST
开盘
2.980
昨收
2.950
最高
3.050
最低
2.960
成交量
22.64万
成交额
--
52周最高
6.06
52周最低
2.720
市值
1.70亿
市盈率(TTM)
-7.6104
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

GALT 新闻

  • Is Galectin Therapeutics Inc. (GALT) Going to Burn These Hedge Funds?
  • Insider Monkey.2019/12/20 23:38
  • Galectin Therapeutics: An Even Better Buy As It Hits 52-Week Lows
  • Seeking Alpha - Article.2019/12/12 21:10
  • The Daily Biotech Pulse: Correvio Faces FDA Panel Rejection, Iterum's Antibiotic Trial Narrowly Misses Primary Endpoint
  • Benzinga.2019/12/11 12:21
  • Galectin Therapeutics Phase 2 NASH Cirrhosis Clinical Trial Results on Belapectin (GR-MD-02) Published in Gastroenterology
  • GlobeNewswire.2019/12/09 13:00

更多

所属板块

生物技术和医学研究
-0.10%
制药与医学研究
+0.07%

热门股票

名称
价格
涨跌幅

GALT 简况

Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company's drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions. It uses naturally occurring, readily-available plant materials as starting material in manufacturing processes to create complex carbohydrates with specific molecular weights and other pharmaceutical properties. The Company has two product candidates, GR-MD-02 and GM-CT-01. The Company's galectin-3 inhibitor is GR-MD-02. The Company is focusing on development of GR-MD-02 intended to be used in the treatment of liver fibrosis associated with fatty liver disease (NASH), moderate to severe plaque psoriasis and in cancer therapy in combination with immune-system modifying agent(s). GM-CT-01 is a compound that continues to be explored in preclinical studies.
展开

Webull提供Galectin Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。